$DRMA
Dermata Therapeutics Inc

2021 Q4 Form 10-Q Financial Statement

#000165495421012206 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.441M $912.5K $377.1K
YoY Change 282.12% 117.47%
% of Gross Profit
Research & Development $1.112M $799.8K $110.0K
YoY Change 910.71% 563.9%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $2.553M $799.8K $491.4K
YoY Change 419.48% 563.9%
Operating Profit -$1.712M
YoY Change 217.05%
Interest Expense $0.00 $651.00 -$38.48K
YoY Change -100.0% -98.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.553M -$1.713M -$396.3K
YoY Change 544.16% 186.73%
Income Tax
% Of Pretax Income
Net Earnings -$2.553M -$1.713M -$396.3K
YoY Change 544.15% 186.73%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$306.5K -$205.7K -$47.58K
COMMON SHARES
Basic Shares Outstanding 8.329M shares 8.329M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.80M $12.60M
YoY Change
Cash & Equivalents $10.80M $12.60M $530.4K
Short-Term Investments
Other Short-Term Assets $825.1K $1.082M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.62M $13.69M $605.5K
YoY Change 1819.87%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $11.62M $13.69M $605.5K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $11.62M $13.69M $605.5K
YoY Change 1819.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $515.2K $769.9K $104.3K
YoY Change 394.12%
Accrued Expenses $1.002M $425.4K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $556.2K
YoY Change -100.0%
Total Short-Term Liabilities $1.517M $1.195M $3.783M
YoY Change -59.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.517M $1.195M $3.783M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.517M $1.195M $3.783M
YoY Change -59.91%
SHAREHOLDERS EQUITY
Retained Earnings -$35.98M -$33.43M -$28.08M
YoY Change 28.14%
Common Stock $833.00 $833.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.11M $12.49M -$3.178M
YoY Change
Total Liabilities & Shareholders Equity $11.62M $13.69M $605.5K
YoY Change 1819.87%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.553M -$1.713M -$396.3K
YoY Change 544.15% 186.73%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$1.804M -$2.210M -$536.0K
YoY Change 236.57% -36.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -620.0 14.39M 313.3K
YoY Change -100.2% 538.3%
NET CHANGE
Cash From Operating Activities -1.804M -2.210M -536.0K
Cash From Investing Activities
Cash From Financing Activities -620.0 14.39M 313.3K
Net Change In Cash -1.805M 12.18M -222.6K
YoY Change 710.51% -1082.93%
FREE CASH FLOW
Cash From Operating Activities -$1.804M -$2.210M -$536.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13685787 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
605453 USD
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8328629 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12603341 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
530400 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1082446 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75053 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
13685787 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
605453 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2021Q3 us-gaap Assets
Assets
13685787 USD
CY2020Q4 us-gaap Assets
Assets
605453 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
769863 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
104276 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
425369 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133477 USD
CY2021Q3 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
0 USD
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
1848495 USD
CY2021Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1140984 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
556160 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1195232 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3783392 USD
CY2021Q3 us-gaap Liabilities
Liabilities
1195232 USD
CY2020Q4 us-gaap Liabilities
Liabilities
3783392 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8328629 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
833 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
45919140 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33429418 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28079798 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
12490555 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
799779 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
120466 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2347564 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1493520 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
912490 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
419596 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2956444 USD
CY2021Q3 drma Redemption Of Series1c Preferred Shares Amount
RedemptionOfSeries1cPreferredSharesAmount
-1000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1187906 USD
CY2021Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1712269 USD
CY2020Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
540062 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
5304008 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2681426 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1712269 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-540062 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5304008 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2681426 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
651 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
57333 USD
us-gaap Interest Expense
InterestExpense
45613 USD
us-gaap Interest Expense
InterestExpense
158791 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1712920 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-597395 USD
us-gaap Net Income Loss
NetIncomeLoss
-5349621 USD
us-gaap Net Income Loss
NetIncomeLoss
-2840217 USD
CY2021Q3 drma Deemed Dividend Upon The Redemption Of Preferred Stock
DeemedDividendUponTheRedemptionOfPreferredStock
269038 USD
CY2020Q3 drma Deemed Dividend Upon The Redemption Of Preferred Stock
DeemedDividendUponTheRedemptionOfPreferredStock
0 USD
drma Deemed Dividend Upon The Redemption Of Preferred Stock
DeemedDividendUponTheRedemptionOfPreferredStock
269038 USD
drma Deemed Dividend Upon The Redemption Of Preferred Stock
DeemedDividendUponTheRedemptionOfPreferredStock
0 USD
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2293199 USD
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2293199 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4275157 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-597395 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7911858 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2840217 USD
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4980306 shares
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1911009 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2945351 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1911009 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-210159 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1421173 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1631332 USD
CY2020Q2 drma Series1 C Preferred Units Issued Unaudited Amount
Series1CPreferredUnitsIssuedUnauditedAmount
250000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-2202981 USD
CY2020Q3 drma Exercise Of Series1a Preferred Warrant Units Amounts
ExerciseOfSeries1aPreferredWarrantUnitsAmounts
18750 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-597395 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-2781626 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-396313 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021Q1 drma Series1d Preferred Units Issued Amount
Series1dPreferredUnitsIssuedAmount
5034801 USD
CY2021Q1 drma Conversion Of Preferred Units To Preferred Stock Amount
ConversionOfPreferredUnitsToPreferredStockAmount
0 USD
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1160049 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2304908 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
712003 USD
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
113987 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1331792 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-505802 USD
CY2021Q3 drma Conversion Of Preferred Stock Warrants To Common Stock Warrants Amount
ConversionOfPreferredStockWarrantsToCommonStockWarrantsAmount
0 USD
CY2021Q3 drma Conversion Of Convertible Debt To Common Stock Amount
ConversionOfConvertibleDebtToCommonStockAmount
180434 USD
CY2021Q3 drma Conversion Of Preferred Stock To Common Stock Amount
ConversionOfPreferredStockToCommonStockAmount
0 USD
CY2021Q3 drma Issuance Of Common Stock And Warrants Net Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetIssuanceCostsAmount
15386189 USD
CY2021Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
142655 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1712920 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
12490555 USD
us-gaap Net Income Loss
NetIncomeLoss
-5349621 USD
us-gaap Net Income Loss
NetIncomeLoss
-2840217 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1416691 USD
us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
14126 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
88293 USD
us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
0 USD
us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
322 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1007393 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5300 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
665587 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-256601 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
371127 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
20936 USD
drma Increase Decrease In License And Settlement Agreement
IncreaseDecreaseInLicenseAndSettlementAgreement
0
drma Increase Decrease In License And Settlement Agreement
IncreaseDecreaseInLicenseAndSettlementAgreement
(500,000
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
1460138 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-652350 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3889483 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3492567 USD
drma Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
15386189 USD
drma Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 USD
drma Redemption Of Series1 C Preferred Stock
RedemptionOfSeries1CPreferredStock
1000000 USD
drma Redemption Of Series1 C Preferred Stock
RedemptionOfSeries1CPreferredStock
0 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-556482 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-462963 USD
us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
0 USD
us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
133592 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1562717 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2314432 USD
drma Proceeds From Issuance Of Series1 D Preferred Units
ProceedsFromIssuanceOfSeries1DPreferredUnits
570000 USD
drma Proceeds From Issuance Of Series1 D Preferred Units
ProceedsFromIssuanceOfSeries1DPreferredUnits
0 USD
drma Net Proceeds From Issuance Of Series1 C Preferred Units
NetProceedsFromIssuanceOfSeries1CPreferredUnits
0 USD
drma Net Proceeds From Issuance Of Series1 C Preferred Units
NetProceedsFromIssuanceOfSeries1CPreferredUnits
250000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18750 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15962424 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2253811 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12072941 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1238756 USD
CY2020Q4 us-gaap Cash
Cash
530400 USD
CY2019Q4 us-gaap Cash
Cash
1991802 USD
CY2021Q3 us-gaap Cash
Cash
12603341 USD
CY2020Q3 us-gaap Cash
Cash
753046 USD
us-gaap Interest Paid
InterestPaid
1420 USD
us-gaap Interest Paid
InterestPaid
51149 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1400 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1400 USD
drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
29936660 USD
drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
0 USD
drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
4464801 USD
drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
0 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2293199 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
180434 USD
us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6582 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2021Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2571428 shares
CY2021Q3 drma Warrants To Purchase One Share Of Common Stock
WarrantsToPurchaseOneShareOfCommonStock
2957142 shares
CY2021Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
65823015 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8328629 shares
drma Reverse Stock Splitpolicytextblock
ReverseStockSplitpolicytextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:left;">On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock shares and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented, and the conversion ratios for the Company’s outstanding preferred stock was adjusted accordingly. See Note 6 – Equity Securities for additional information.</p>
CY2021Q3 drma Accumulated Deficit
AccumulatedDeficit
-33400000 USD
CY2020 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
4000000.0 USD
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
3900000 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:left;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2600000 USD
drma Schedule Of Potentially Dilutive Securities
ScheduleOfPotentiallyDilutiveSecurities
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, </strong><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1 Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336,882</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1a Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">244,811</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1a Preferred Warrant </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">69,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1b Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">317,058</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1c Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,270,866</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1d Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Class B Common Units Profits Interests</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">365,245</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common Stock Options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common Stock Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,091,657</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total potentially dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,614,856</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,604,074</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
3000000 USD
CY2020Q4 us-gaap Notes Payable
NotesPayable
1145000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1730000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
125000 USD
CY2020Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.04 pure
CY2020Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-07-17
CY2021Q1 drma Discount Rate For Preferred Shares
DiscountRateForPreferredShares
10000000 USD
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-12-31
CY2021Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1255000 USD
CY2021Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
311000 USD
CY2019Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2021Q1 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8328629 shares
CY2019Q2 us-gaap Preferred Units Issued
PreferredUnitsIssued
5221156 shares
CY2021Q2 drma Common Stock Shares Available For Issuances
CommonStockSharesAvailableForIssuances
593340 shares
CY2021Q3 drma Common Stock Shares Available For Issuances Increased
CommonStockSharesAvailableForIssuancesIncreased
1648213 shares
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
269038 USD
CY2021Q3 drma Common Stocks Shares Authorized
CommonStocksSharesAuthorized
90000000 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2957142 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.00
drma Warrant Expire
WarrantExpire
which expire August 17, 2026
CY2021Q3 drma Common Stock Warrant Issued
CommonStockWarrantIssued
69212 shares
CY2021Q3 drma Common Stock Warrant Issued
CommonStockWarrantIssued
69212 shares
CY2021Q3 drma Series1 A Preferred Warrants Exercise Price
Series1APreferredWarrantsExercisePrice
20.50
drma Series1 A Preferred Warrants Expire
Series1APreferredWarrantsExpire
which expire November 15, 2026
CY2021Q1 drma Class B Common Units Profits Interests Converted Due To The Conversion From An Llc To Ac Corporation
ClassBCommonUnitsProfitsInterestsConvertedDueToTheConversionFromAnLlcToACCorporation
277448 shares
CY2021Q1 drma Class B Common Units Profits Interests Converted Into Options
ClassBCommonUnitsProfitsInterestsConvertedIntoOptions
277448 shares
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1339993 USD
drma Unrecognized Future Stock Based Compensation Expense
UnrecognizedFutureStockBasedCompensationExpense
1400000 USD
drma Expected Lenght Of Recognized Term
ExpectedLenghtOfRecognizedTerm
P2Y10M24D
CY2020Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1145000 USD
us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
1255000 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
2300000 USD

Files In Submission

Name View Source Status
0001654954-21-012206-index-headers.html Edgar Link pending
0001654954-21-012206-index.html Edgar Link pending
0001654954-21-012206.txt Edgar Link pending
0001654954-21-012206-xbrl.zip Edgar Link pending
drma-20210930.xsd Edgar Link pending
drma-20210930_cal.xml Edgar Link unprocessable
drma-20210930_def.xml Edgar Link unprocessable
drma-20210930_lab.xml Edgar Link unprocessable
drma-20210930_pre.xml Edgar Link unprocessable
drma_10q.htm Edgar Link pending
drma_10q_htm.xml Edgar Link completed
drma_ex101.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending